Serum Biomarkers of Erectile Dysfunction in Diabetes Mellitus: A Systematic Review of Current Literature
- 1 July 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 5 (3) , 339-348
Abstract
Erectile dysfunction (ED) is a common complication in patients with diabetes mellitus (DM). However, the utility of serum biomarkers as clinical surrogates for the development and/or progression of ED is unknown. To summarize the current literature for serum biomarkers for ED in DM and emphasize areas for future research. Human subject data demonstrating the utility of serum markers for the development and progression of ED in patients with DM. We performed a systematic PubMed-Medline search in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement using Medical Subject Headings (MeSH) for articles published from January 1, 2000 through December 31, 2016 of serum biomarkers for development or progression of ED in patients with DM using erectile dysfunction [MeSH] AND (biomarkers [MeSH] or inflammation mediators [MeSH] or intercellular signaling peptides and proteins [MeSH] or cell adhesion molecules [MeSH]). A thorough review of these studies was completed. Of the 327 abstracts screened, 12 full-text studies were assessed and 1 study was excluded. Eleven studies assessing serum biomarkers for ED in patients with DM were included in this review. The most studied serum biomarkers for ED in men with DM included endothelial dysfunction markers such as serum E-selectin, endothelial progenitor cells, and endothelial microparticles and specific markers of inflammation such as interleukin-10, ratio of tumor necrosis factor-α to interleukin-10, and reactive oxygen species such as nitric oxide and malondialdehyde. Reliable serum biomarkers will enable earlier diagnosis and objective monitoring of disease progression and responses to treatment in patients with ED. Serum biomarkers for ED in men with DM are very limited. Future longitudinal studies with uniform patient characteristics are needed to evaluate the potential clinical use of serum biomarkers in men with DM for the development and progression of ED. Patel DP, Craig JR, Myers JB, et al. Serum Biomarkers of Erectile Dysfunction in Diabetes Mellitus: A Systematic Review of Current Literature. Sex Med Rev 2017:5:339-348.Keywords
This publication has 28 references indexed in Scilit:
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease PredictionNew England Journal of Medicine, 2012
- The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular DiseaseMayo Clinic Proceedings, 2012
- What are biomarkers?Current Opinion in HIV and AIDS, 2010
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Is erectile dysfunction a low-grade systemic inflammatory condition?European Heart Journal, 2006
- Infection induced inflammation is associated with erectile dysfunction in men with diabetesEuropean Journal of Clinical Investigation, 2006
- Endothelial Dysfunction and Low-Grade Inflammation Explain Much of the Excess Cardiovascular Mortality in Individuals With Type 2 DiabetesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Endothelial and Erectile Dysfunction, Diabetes Mellitus, and the Metabolic Syndrome: Common Pathways and Treatments?The American Journal of Cardiology, 2005
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998